Global Corifollitropin Alfa Sales Market Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Corifollitropin Alfa Sales Market Report 2024
Market Analysis and InsightsGlobal Corifollitropin Alfa Market
Corifollitropin alfa is a hybrid follicle-stimulating hormone (FSH) molecule, which is used to treat infertility. This molecule when injected results in the development of a high number of metaphase II oocytes in women.
Due to the COVID-19 pandemic, the global Corifollitropin Alfa market size is estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, 100μg/0.5ml accounting for % of the Corifollitropin Alfa global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospitals segment is altered to an % CAGR throughout this forecast period.
The United States Corifollitropin Alfa market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Corifollitropin Alfa include Merck, Schering-Plough and Ferring, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Corifollitropin Alfa Scope and Market Size
The global Corifollitropin Alfa market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Corifollitropin Alfa market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
100μg/0.5ml
150μg/0.5ml
Hospitals
Laboratories
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
Merck
Schering-Plough
Ferring
Corifollitropin alfa is a hybrid follicle-stimulating hormone (FSH) molecule, which is used to treat infertility. This molecule when injected results in the development of a high number of metaphase II oocytes in women.
Due to the COVID-19 pandemic, the global Corifollitropin Alfa market size is estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, 100μg/0.5ml accounting for % of the Corifollitropin Alfa global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospitals segment is altered to an % CAGR throughout this forecast period.
The United States Corifollitropin Alfa market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Corifollitropin Alfa include Merck, Schering-Plough and Ferring, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Corifollitropin Alfa Scope and Market Size
The global Corifollitropin Alfa market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Corifollitropin Alfa market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
100μg/0.5ml
150μg/0.5ml
Segment by Application
Hospitals
Laboratories
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Merck
Schering-Plough
Ferring